PDS Biotechnology's top three insider shareholders as of September 29, 2026 are Frank Bedu-Addo (President/Ceo, 690.87K shares), Stephen C. Glover (Director, 78.85K shares), Gregory Gene Freitag (Director, 61.21K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frank Bedu-Addo | President/Ceo | 690,866 | 0 | 690,866 | 82.0% | 02 Dec, 2022 |
| 2 | Stephen C. Glover | Director | 78,851 | 0 | 78,851 | 9.4% | 03 Mar, 2025 |
| 3 | Gregory Gene Freitag | Director | 61,213 | 0 | 61,213 | 7.3% | 03 Mar, 2025 |
| 4 | Matthew C Hill | Chief Financial Officer | 3,875 | 8,050 | 11,925 | 1.4% | 14 Dec, 2021 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 12 Jan, 2026 | Gregory Conn | Chief Scientific Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 12 Jan, 2026 | Lars Boesgaard | Chief Financial Officer | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Frank Bedu-Addo | President/Ceo | Acquired A | 548,782 | $0.00 | $0 | 548,782 | Direct |
| 12 Jan, 2026 | Stephan Toutain | Chief Operating Officer | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Otis W Brawley | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Kamil Ali-Jackson | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Stephen C. Glover | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Ilian Iliev | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jan, 2026 | Kirk V. Shepard | Chief Medical Officer | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Spencer D. Brown | Senior Vp, General Counsel | Acquired A | 300,000 | $0.00 | $0 | 300,000 | Direct |
| 12 Jan, 2026 | Gregory Gene Freitag | Director | Acquired A | 54,876 | $0.00 | $0 | 54,876 | Direct |
| 12 Jun, 2025 | Kirk V. Shepard | Chief Medical Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 12 Jun, 2025 | Lars Boesgaard | Chief Financial Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 12 Jun, 2025 | Stephan Toutain | Chief Operations Officer | Acquired A | 150,000 | $0.00 | $0 | 150,000 | Direct |
| 11 Jun, 2025 | Stephen C. Glover | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 11 Jun, 2025 | Ilian Iliev | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 11 Jun, 2025 | Kamil Ali-Jackson | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 11 Jun, 2025 | Gregory Gene Freitag | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 11 Jun, 2025 | Otis W Brawley | Director | Acquired A | 22,700 | $0.00 | $0 | 22,700 | Direct |
| 28 Feb, 2025 | Stephen C. Glover | Director | Acquired P | 15,061 | $1.66 | $25.00K | 78,851 | Direct |